{"id":"W4411394543","doi":"10.1016/j.ard.2025.06.020","title":"POS0659 EFFICACY, SAFETY AND IMMUNOGENICITY OF THE PROPOSED TOCILIZUMAB BIOSIMILAR RGB-19, INTRAVENOUSLY ADMINISTERED TO PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS: WEEK 24 DATA FROM A PHASE 3 STUDY","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Biosimilar; Tocilizumab; Immunogenicity; Rheumatoid arthritis; Pharmacology; Immunology; Internal medicine; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003580815,0.0008747902,0.001845338,0.0002784164,0.0004991153,0.0008005641,0.0006563928,0.001927156,0.006255859],"category_scores_gemma":[0.002165432,0.0004663719,0.00159047,0.000349612,0.001121002,0.0009837319,0.0003230085,0.002384844,0.002059665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005417051,"about_ca_system_score_gemma":0.0009750767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002859462,"about_ca_topic_score_gemma":0.0005111762,"domain_scores_codex":[0.9984755,0.0008894053,0.0001386622,0.0001841728,0.0001842041,0.0001279471],"domain_scores_gemma":[0.9983574,0.000410102,0.0004313003,0.000173518,0.0001862459,0.0004414624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9160818,0.01574859,0.002060779,0.0006885349,0.0008182166,0.00009501735,0.0001369809,0.0004265597,0.02241811,0.0000993654,0.001295312,0.04013077],"study_design_scores_gemma":[0.4598179,0.525955,0.008098573,0.0000532442,0.0005653173,0.0001978385,0.00004148522,0.0003663882,0.002870926,0.0001405204,0.001861892,0.00003089103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906007,0.002393234,0.0009266462,0.0002276807,0.000124779,0.002556169,0.001370841,0.00008905076,0.001710779],"genre_scores_gemma":[0.9886411,0.00118749,0.002086336,0.0007330694,0.0001459846,0.003438353,0.001882629,0.00003439382,0.001850602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006255859,"threshold_uncertainty_score":0.02092797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09250792226928192,"score_gpt":0.3679126803776471,"score_spread":0.2754047581083652,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}